IL32 and hepatocellular carcinoma: Another research team reports a correlation between circulating IL-32 and the area of VEGF staining in the HCC tissues, suggesting that IL-32 may also augment the development of HCC via boosting neovascularisation, which offers some evidence for the management of HCC patients with combined anti-IL32 and anti-VEGF therapy (32).